Alector, INC 8-K filings

Alector announced its second quarter 2026 financial results, reporting $172.8 million in cash and cash equivalents, sufficient to fund operations through 2027, while detailing progress in its Alector Brain Carrier (ABC) platform and related drug candidates.

Alector, Inc. announced the termination of its collaboration agreement with Glaxo Wellcome UK Limited (GSK) and the full repayment of its loan facility with Hercules Capital, Inc.

Alector, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of Class II directors and the ratification of its independent auditor.

Alector, Inc. has entered into a new sales agreement with TD Securities (USA) LLC to offer and sell up to $125 million of its common stock from time to time.

Alector, Inc. announced its fourth quarter and full year 2025 financial results, reporting a significant increase in net loss while advancing its Alector Brain Carrier (ABC) platform and clinical programs.

Alector, Inc. has officially appointed Neil Berkley as its Chief Financial Officer, effective December 10, 2025, solidifying his interim role.

Alector, Inc. reported third quarter 2025 financial results, highlighted by a strategic pivot to its Alector Brain Carrier (ABC) platform, a workforce reduction, and extended cash runway through 2027 despite a Phase 3 trial failure.

Alector announced its Phase 3 INFRONT-3 trial for latozinemab in FTD-GRN did not meet its clinical co-primary endpoint, leading to a 49% workforce reduction and R&D head resignation.

Alector, Inc. announced its second quarter 2025 financial results, reporting a reduced net loss and maintaining a strong cash position, while confirming key clinical trial milestones are on track.

Alector, Inc. announced the resignation of its Chief Financial Officer, Dr. Marc Grasso, effective June 20, 2025, with Neil Berkley appointed Interim CFO and Grace Wong-Sarad as Principal Accounting Officer, while also confirming progress in its late-stage clinical programs and successful stockholder votes.

Alector announces its Q1 2025 financial results, provides a business update, and extends its cash runway into the second half of 2027.

Dr. Gary Romano, Chief Medical Officer of Alector, Inc., has announced his resignation, effective April 25, 2025, to pursue other opportunities.

Alector, Inc. plans to reduce its workforce by approximately 13% as part of cost reduction initiatives to align resources with strategic priorities.

Alector reports financial results for Q4 and full year 2024, highlighting progress in clinical trials and a strong cash position.

Alector and AbbVie have terminated their collaboration on the TREM2 program for Alzheimer's disease after a Phase 2 trial failed to meet its primary endpoint.

Alector is discontinuing the long-term extension of its INVOKE-2 Alzheimer's trial and reducing its workforce by 17% after the trial failed to meet its primary endpoint.

Alector, a clinical-stage biotechnology company, has entered into a debt financing agreement with Hercules Capital for up to $50 million to support its immuno-neurology programs.

Alector reported its third quarter 2024 financial results, highlighting progress in its clinical programs and a strong cash position.

Alector announced its second quarter 2024 financial results and provided updates on its clinical programs, including progress in Alzheimer's and frontotemporal dementia trials.

Alector, Inc. held its 2024 annual meeting where stockholders elected directors, ratified the appointment of Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis.

Alector announced its first quarter 2024 financial results, provided updates on its clinical programs, and strengthened its leadership team.

Alector Inc. reports the resignation of a director and the appointment of two new directors to its Board, effective March 20 and March 19, 2024, respectively.

Alector announced its fourth quarter and full year 2023 financial results, highlighted by a strengthened cash position and progress in clinical trials for neurodegenerative diseases.

Alector, a clinical-stage biotechnology company, has announced the pricing of a public offering of 10,869,566 shares of its common stock, expected to generate gross proceeds of $75 million.

Alector Inc. reports a preliminary cash balance of $549 million as of December 31, 2023, anticipating sufficient funds to cover operations into the second half of 2026.